FDA Approved: TABRECTA — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approved a supplemental application for Tabrecta (capmatinib) from Novartis Pharmaceuticals Corporation. The action relates to Tabrecta's approved use in tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tabrecta (Capmatinib)

Snippet

SUPPL AP for TABRECTA (CAPMATINIB)